166 related articles for article (PubMed ID: 32563127)
1. Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders.
Chengyu L; Weixiong S; Chao C; Songyan L; Lin S; Zhong Z; Hua P; Fan J; Na C; Tao C; Jianwei W; Haitao R; Hongzhi G; Xiaoqiu S
J Neuroimmunol; 2020 Aug; 345():577289. PubMed ID: 32563127
[TBL] [Abstract][Full Text] [Related]
2. A case report of anti-GAD65 antibody-positive autoimmune encephalitis in children associated with autoimmune polyendocrine syndrome type-II and literature review.
Sapana T; Li W; Tian F; Yan W; Dou B; Hua S; Zhuo Z
Front Immunol; 2023; 14():1274672. PubMed ID: 38077387
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity.
Gresa-Arribas N; Ariño H; Martínez-Hernández E; Petit-Pedrol M; Sabater L; Saiz A; Dalmau J; Graus F
PLoS One; 2015; 10(3):e0121364. PubMed ID: 25774787
[TBL] [Abstract][Full Text] [Related]
4. The neurological syndromes associated with glutamic acid decarboxylase antibodies.
Baizabal-Carvallo JF
J Autoimmun; 2019 Jul; 101():35-47. PubMed ID: 31000408
[TBL] [Abstract][Full Text] [Related]
5. GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders.
Fouka P; Alexopoulos H; Akrivou S; Trohatou O; Politis PK; Dalakas MC
J Neuroimmunol; 2015 Apr; 281():73-7. PubMed ID: 25867471
[TBL] [Abstract][Full Text] [Related]
6. Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment.
Muñoz-Lopetegi A; de Bruijn MAAM; Boukhrissi S; Bastiaansen AEM; Nagtzaam MMP; Hulsenboom ESP; Boon AJW; Neuteboom RF; de Vries JM; Sillevis Smitt PAE; Schreurs MWJ; Titulaer MJ
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32123047
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal-specific glutamic acid decarboxylase antibodies at low titers in autoimmune neurological disorders.
Sunwoo JS; Chu K; Byun JI; Moon J; Lim JA; Kim TJ; Lee ST; Jung KH; Park KI; Jeon D; Jung KY; Kim M; Lee SK
J Neuroimmunol; 2016 Jan; 290():15-21. PubMed ID: 26711563
[TBL] [Abstract][Full Text] [Related]
8. GAD65 neurological autoimmunity.
McKeon A; Tracy JA
Muscle Nerve; 2017 Jul; 56(1):15-27. PubMed ID: 28063151
[TBL] [Abstract][Full Text] [Related]
9. GAD antibodies in neurological disorders - insights and challenges.
Graus F; Saiz A; Dalmau J
Nat Rev Neurol; 2020 Jul; 16(7):353-365. PubMed ID: 32457440
[TBL] [Abstract][Full Text] [Related]
10. Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
Jones AL; Flanagan EP; Pittock SJ; Mandrekar JN; Eggers SD; Ahlskog JE; McKeon A
JAMA Neurol; 2015 Nov; 72(11):1304-12. PubMed ID: 26414229
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in a case of low titre GAD65 antibody-associated spectrum neurological disorders.
Wei M; Bannout F; Dastjerdi M; Phan C; Batarseh S; Guo X; Baker N
BMJ Case Rep; 2024 Jun; 17(6):. PubMed ID: 38871638
[TBL] [Abstract][Full Text] [Related]
12. [Pediatric autoimmune encephalitis associated with anti-glutamic acid decarboxylase 65 antibody: two cases report and literature review].
Ren CH; Ren HT; Ren XT; Zhang WH; Li JW; Dai LF; Chen CH; Guan HZ; Fang F
Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):47-52. PubMed ID: 33397004
[No Abstract] [Full Text] [Related]
13. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.
Ariño H; Gresa-Arribas N; Blanco Y; Martínez-Hernández E; Sabater L; Petit-Pedrol M; Rouco I; Bataller L; Dalmau JO; Saiz A; Graus F
JAMA Neurol; 2014 Aug; 71(8):1009-16. PubMed ID: 24934144
[TBL] [Abstract][Full Text] [Related]
14. Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis.
Hansen N; Widman G; Witt JA; Wagner J; Becker AJ; Elger CE; Helmstaedter C
Epilepsy Behav; 2016 Dec; 65():18-24. PubMed ID: 27855355
[TBL] [Abstract][Full Text] [Related]
15. Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology.
Dubey D; Alqallaf A; Hays R; Freeman M; Chen K; Ding K; Agostini M; Vernino S
JAMA Neurol; 2017 Apr; 74(4):397-402. PubMed ID: 28166327
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of high titer of GAD65 antibodies in a case of limbic encephalitis.
Di Giacomo R; Deleo F; Pastori C; Didato G; Andreetta F; Del Sole A; de Curtis M; Villani F
J Neuroimmunol; 2019 Dec; 337():577063. PubMed ID: 31525619
[TBL] [Abstract][Full Text] [Related]
17. Intravenous methylprednisolone or immunoglobulin for anti-glutamic acid decarboxylase 65 antibody autoimmune encephalitis: which is better?
Li TR; Zhang YD; Wang Q; Shao XQ; Li ZM; Lv RJ
BMC Neurosci; 2020 Mar; 21(1):13. PubMed ID: 32228575
[TBL] [Abstract][Full Text] [Related]
18. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction.
Pittock SJ; Yoshikawa H; Ahlskog JE; Tisch SH; Benarroch EE; Kryzer TJ; Lennon VA
Mayo Clin Proc; 2006 Sep; 81(9):1207-14. PubMed ID: 16970217
[TBL] [Abstract][Full Text] [Related]
19. Glutamic acid decarboxylase autoantibodies and neurological disorders.
Vianello M; Tavolato B; Giometto B
Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune encephalitis associated with glutamic acid decarboxylase antibodies: a case series.
Incecik F; Herguner OM; Besen S; Yılmaz M
Acta Neurol Belg; 2018 Sep; 118(3):411-414. PubMed ID: 29349679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
